Sanket Koul

Metlife GCC leases 75,000 sq ft in Noida's Oxygen Business Park

Metlife's global capacity centre has leased 75,000 sq ft at Embassy's Oxygen Business Park in Noida, adding to strong Grade-A office demand amid rising GCC activity and tech sector expansion

Embassy REIT raises ₹1,400 cr via 10-year NCD to boost long-term capital

Embassy REIT has raised ₹1,400 crore through a fully subscribed 10-year NCD issue, expanding its institutional investor base as the trust continues to secure long-duration capital

American business schools rewrite syllabus as Indian enrolments fall

Joint degrees and credit-sharing emerge as response to visa curbs and a 45% drop

Centre aiming to quadruple intake of foreign students in India by 2030

At least 2-3 more foreign universities to open campuses in India this year

Drugmakers may review shipment schedules to West Asia if conflict drags on

Indian drugmakers are reviewing shipment schedules and inventories for West Asia as escalating tensions threaten sea and air routes, raising freight costs and risking supply delays

Gaurs Group to invest ₹250 cr for precast manufacturing plant in Noida

Gaurs Group will invest Rs 250 crore to build a precast and modular construction facility in Noida after signing an MoU with Elematic India, aiming to boost efficiency and project timelines

Realty major TARC eyes phased launches in Delhi, Gurugram markets in FY27

TARC will prioritise Delhi and Gurugram in FY27 with phased launches across existing luxury projects, backed by strong demand momentum and projected cash-flow visibility over four years

Novo Nordisk, Abbott tie up to launch second Ozempic brand in India

Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry

NBCC inks MoUs with DDA for ₹775 crore redevelopment of staff colonies

NBCC has signed two MoUs with DDA for redeveloping staff colonies at Old Rajinder Nagar and Safdarjung Development Area, securing Rs 775 crore in projects under a self-sustainable model

CDSCO allows immediate lab testing of drugs to speed up approvals

CDSCO will permit drugmakers to begin testing samples as soon as applications are filed, shifting detailed scrutiny to later stages to shorten approval timelines and ease compliance

India may retain $113 bn forex as foreign universities set up campuses

A Knight Frank-Deloitte report says foreign universities establishing campuses in India could help retain $113 billion in foreign currency by 2040, easing large outflows for overseas education

Eris Life partners Natco Pharma to launch semaglutide generic in India

Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense competition in metabolic and weight-loss therapies

Centre to roll out free HPV vaccine drive for 14-year-old girls nationwide

India will launch a nationwide, free and voluntary HPV vaccination campaign for 14-year-old girls, using Gardasil under strict quality norms, as part of efforts to eliminate cervical cancer

Ghaziabad, Meerut the new prime addresses for real estate companies

Firms upbeat as Delhi-Meerut RRTS now fully operational

Gurugram overtakes Mumbai to become India's top luxury housing market

Gurugram has surpassed Mumbai in luxury housing sales for the first time in five years, driven by HNI demand, new micro-markets and major infrastructure upgrades, a new report shows

Morepen Labs wins ₹825 crore long-term CDMO deal with global drugmaker

Morepen Labs has secured a ₹825 crore multi-year CDMO mandate from a global pharma major, with supplies set to begin in 4-5 months and execution running through Q1 FY27

US tariff uncertainty: Auto, medtech exporters on wait-and-watch mode

Indian auto and medical device exporters adopt wait-and-watch approach as US tariff shifts and refund uncertainty cloud shipment decisions

NCLT clears withdrawal of insolvency proceedings against Mahagun

The decision follows the company's settlement with IDBI Trusteeship Services; the NCLT order further records that all pending applications in the matter stand disposed of

Indian pharma may face muted US growth in FY27 on gRevlimid pressure

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry

Luxury shift drives 17% rise in average apartment sizes across top cities

Premiumisation of housing fuels demand for larger units, with NCR, Chennai and Bengaluru posting the sharpest gains in average apartment sizes over two years